Lilly raises full-year earnings forecasts on surging demand for weight-loss drug

Eli Lilly upgraded its full-year profit and sales outlook, now forecasting $21.75-$23 per share and $60-$62 billion in revenue, fueled by surging demand for its weight-loss drug Zepbound ($3.38B Q2 sales) and strong Mounjaro sales ($5.20B Q2 sales) that exceeded expectations. Despite this positive guidance and increased market share in incretins, LLY shares declined over 10% premarket following disappointing Phase 3 trial data for its oral weight-loss candidate, orforglipron, which demonstrated lower efficacy (12.4% weight loss) than Novo Nordisk's competing Wegovy, impacting investor sentiment regarding Lilly's broader GLP-1 pipeline.

Analysis

Eli Lilly (LLY) has presented a bifurcated outlook, marked by exceptional current performance contrasted with emerging pipeline concerns. The company significantly raised its full-year guidance, now anticipating adjusted EPS of $21.75-$23.00 and revenue of $60-$62 billion, driven by outsized demand for its GLP-1 franchise. This strength is evidenced by second-quarter sales for Mounjaro ($5.20 billion) and Zepbound ($3.38 billion) that substantially beat analyst estimates. Furthermore, Lilly's competitive execution is clear, having captured 57% of the U.S. incretins market and seeing weekly Zepbound prescriptions (418,597) significantly outpace Novo Nordisk's Wegovy (281,725). Despite this operational momentum, the stock declined over 10% premarket. This negative reaction was catalyzed by disappointing trial data for its oral weight-loss candidate, orforglipron, which showed a 12.4% weight loss, underperforming both expectations and the 14.9% benchmark set by Novo's Wegovy. This suggests the market is pricing in a significant risk to Lilly's long-term dominance in the GLP-1 space, prioritizing future pipeline potential over current earnings beats.

Key Decisions for Investors

• Investors should weigh the company's strong current earnings momentum and upwardly revised guidance against the significant market disappointment regarding the oral orforglipron pipeline, which caused the premarket share price decline.
• The underperformance of orforglipron relative to competitor products introduces a new risk factor to Lilly's long-term growth narrative, potentially creating a competitive opening for Novo Nordisk in the next-generation oral GLP-1 market.
• Monitor weekly prescription data for Zepbound and Mounjaro closely, as continued market share gains in the injectable segment are now critical to support the valuation, especially given the new uncertainty surrounding the oral pipeline.